Insulet Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PODD research report →
Range $144 – $235
Price Chart
About the company
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
- CEO
- Ashley McEvoy
- IPO
- 2007
- Employees
- 5,400
- HQ
- Acton, MA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a recovery phase, rebounding well above its 50-day average after a sharp reset from the 52-week high. It still trades below the 200-day line, so the longer-term trend remains unfinished rather than fully repaired.
Street sentiment is constructive but not euphoric: the consensus sits at Buy with an average target around 178.6, above the current share price. Recent changes lean mixed-to-positive, with Jefferies and TD Cowen lifting targets while Barclays initiated at Equal Weight and several firms trimmed views in August.
The earnings profile is strong, with 8 straight EPS beats and the latest quarter topping estimates by 25.2%. Analysts still expect EPS to rise to 7.91 next year, so shareholders should watch whether Omnipod demand keeps supporting another beat-and-raise pattern.
The pattern leans mildly positive, led by discretionary buying from the CEO and one director, while the rest is mostly awards, in-kind transfers, and vesting noise. The only clear sale was a modest director disposal, which does not outweigh the recent net buying tone.
Profitability is solid, with a 71.9% gross margin, 18.4% operating margin, and 13.4% net margin. Growth remains healthy too, with revenue up 19.2% year over year and EPS up 63.7%, while free cash flow reached $760.9 million in 2025.
PODD stands out for premium margins and strong cash generation versus most medical-device peers, but it also carries a valuation premium at about 26x earnings. The setup favors quality-growth investors, though the stock still needs to prove it can reclaim its longer-term trend.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.24B
- P/E
- 22.26
- Fwd P/E
- 19.56
- PEG
- 0.29
- P/S
- 2.98
- P/B
- 6.01
- EV/EBITDA
- 14.39
- Div Yield
- 0.00%
- Gross Margin
- 71.88%
- Op Margin
- 18.43%
- Net Margin
- 13.45%
- ROE
- 29.48%
- ROIC
- 17.53%
Latest fiscal year · YoY change
- Revenue
- $2.71B+30.7%
- Gross Profit
- $1.94B+34.2%
- Op Income
- $473.80M
- Net Income
- $247.10M-40.9%
- EPS
- $3.51-41.2%
- OCF Growth
- +32.3%
- FCF Growth
- +23.7%
- 52W High
- $342.13
- 52W Low
- $126.40
- 50D MA
- $142.25
- 200D MA
- $170.47
- Beta
- 1.06
- RSI (14)
- 36
- Avg Volume
- 1.60M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Insulet posted a strong Q3 with nearly 20% revenue growth, record gross margin, and raised full-year guidance to the top end of its prior range while signaling a more conservative 2027 outlook.· November 4, 2026
- Q3 revenue was $842 million, up 19.2% reported and 19.6% constant currency, with adjusted EPS of $1.99, up 60% from $1.24.
- Adjusted gross margin reached 74.2% and adjusted operating margin was 22%, up 200 and 490 basis points year over year, respectively.
- U.S. Omnipod revenue grew 14.7% and international revenue grew 31.7% reported, 33% constant currency; customer base growth exceeded 20%.
- Management narrowed 2026 guidance to the high end of its prior range and expects full-year constant currency revenue growth of 21% to 22% for the company.
- The company outlined a more cautious 2027 framework due to tougher comps, new competition, and the timing of Omnipod 6, while still expecting top-tier growth and profitability expansion.
Insulet reported third-quarter revenue of $842 million, up 19.2% reported and 19.6% constant currency year over year. Adjusted EPS was $1.99, up 60% from $1.24 last year. Adjusted gross margin was 74.2%, up 200 basis points, and adjusted operating margin was 22%, up 490 basis points. U.S. Omnipod revenue increased 14.7%, while international Omnipod revenue grew 31.7% reported and 33% constant currency. For 2026, management now expects total company constant currency revenue growth of 21% to 22%, total Omnipod growth of 21.5% to 22.5%, U.S. Omnipod growth of 17.5% to 18.5%, and international Omnipod growth of 32% to 33% constant currency. They also expect about 150 basis points of adjusted operating margin expansion, adjusted EPS growth of more than 30%, and free cash flow of about $275 million. For Q4, they guided to total company revenue growth of 13.5% to 17% and total Omnipod growth of 13% to 16.5%.
Ashley McEvoy said the quarter showed strength across the business, with U.S. performance in range and international performance ahead of plan, allowing the company to narrow full-year outlook to the top end of the prior range. She emphasized that Insulet remains a leader in a large, underpenetrated AID market and said Omnipod continues to win a leading share of MDI converts to AID. Her tone was confident and strategic, but she was clear that 2027 growth should moderate because of tougher comparisons, new competition, and the timing of innovation, especially Omnipod 6.
Flavia Pease highlighted the quarter’s leverage: revenue of $842 million, adjusted gross margin of 74.2%, adjusted operating margin of 22%, and adjusted EPS of $1.99. She said the quarter benefited from stable pricing, customer base growth of more than 20%, low-single-digit new customer starts, and a 250-basis-point benefit from reserve adjustments, including about $3 million in France and about $2 million in Canada. On cash, she noted $584 million in cash and investments, the revolver upsized to $750 million, $212 million of year-to-date free cash flow, and a plan to fund $400 million of Q4 share repurchases with excess cash. She also said 2026 free cash flow is expected to be about $275 million, with the company planning roughly 70 million shares outstanding.
Analysts pressed management on why 2027 growth was being framed more conservatively and how much was due to conservatism versus real business headwinds. Management said the lower outlook reflects a stronger 2026 base, the pacing of innovation, new competition, and a more measured assumption on market growth, while still expecting top-tier growth and EPS expansion. Questions also focused on type 2 retention and whether tighter sampling and customer-care changes could slow new starts; management said the new governance, retention specialists, and compensation changes are already showing early improvement in type 2 retention, with benefits expected to build over time.
The bull case from this call is that Insulet is still growing quickly from a large base, with strong customer base expansion, record margin performance, and continued market share leadership in AID. Management also described a robust innovation pipeline, including Omnipod Discover, the Omnipod 6 launch in 2027, and a fully closed-loop type 2 program, all of which they believe can extend growth and profitability.
The main risks discussed were a more competitive 2027, tougher international comparisons, and slower growth as the company laps its strongest year and waits for new products to scale. Management also acknowledged execution issues in type 2, including weaker retention trends earlier in the year, and said it does expect to lose a few share points in new customer starts as competitors enter the market.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 69.37M
- Float Shares
- 69.07M
of shares held by institutions
757 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for PODD, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Oct 20, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Sep 18, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 25, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 18, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 4, 25 | Filing → |
| Markwayne MullinSenate · OK | Sell | Jan 4, 24 | Filing → |
| Markwayne MullinSenate · OK | Sell | Dec 22, 23 | Filing → |
| Markwayne MullinSenate · OK | Buy | Jan 3, 23 | Filing → |
| Tina SmithSenate · MN | Sell | Apr 4, 24 | Filing → |
| Markwayne MullinSenate · OK | Sell | Dec 22, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 8.70M | ▼ 94.73K |
| Blackrock, Inc. | 5.88M | ▼ 810.96K |
| Vanguard Capital Management LLC | 4.54M | ▲ 17.54K |
| Vanguard Portfolio Management LLC | 3.00M | ▼ 75.46K |
| State Street Corp | 2.72M | ▼ 474.62K |
| Aqr Capital Management LLC | 2.46M | ▲ 856.41K |
| Arrowstreet Capital, Limited Partnership | 2.28M | ▲ 808.14K |
| Two Sigma Investments, LP | 1.90M | ▲ 1.14M |
| Invesco Ltd. | 1.90M | ▲ 208.00K |
| Geode Capital Management, LLC | 1.85M | ▼ 158.56K |
| T. Rowe Price Investment Management, Inc. | 1.51M | ▼ 303.58K |
| Morgan Stanley | 1.24M | ▼ 241.54K |
Held by 1,070 ETFs
Biggest fund positions in PODD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Pease Flavia | other | 1,882 |
| Sep 30, 26 | MAZELSKY JONATHAN JAY | other | 141 |
| Sep 30, 26 | Huffines Robert Luther | other | 178 |
| Aug 21, 26 | McEvoy Ashley | buy | 1,100 |
| Aug 1, 26 | Davis Lisa Blair | other | 244 |
| Jun 30, 26 | Huffines Robert Luther | other | 151 |
| Jul 1, 26 | MAZELSKY JONATHAN JAY | other | 1,355 |
| Jul 1, 26 | MAZELSKY JONATHAN JAY | other | 0 |
| Jun 30, 26 | Huffines Robert Luther | other | 144 |
| Jun 3, 26 | STONESIFER TIMOTHY C. | buy | 2,790 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PODD coverage
Recent articles, reports, and earnings notes.
Insulet (PODD): Omnipod Growth Meets Valuation Risk
Insulet is delivering strong Omnipod growth, expanding margins, and rising EPS, but management is already signaling slower growth ahead. The stock looks attractive for long-term investors, though valuation leaves less room for error.

MiniMed Group IPO: The Bull and Bear Case for a Diabetes Carve-Out
MiniMed Group, Inc. Common Stock When Issued is expected to list on NASDAQ on 2026-10-01 under the symbol MMEDV. The price range has not been disclosed yet. The bull case is a global diabetes-tech platform with $3.102 billion in fiscal 2026 sales; the bear case is execution risk, heavy competition, and a float dominated by Medtronic.

Insulet's 20% plunge is the guidance cut bulls cannot explain
Insulet's 20.12% selloff reflects a credibility hit to its U.S. growth engine, not merely a disappointing trading session. The FY2026 guidance cut makes the Omnipod runway harder to underwrite, even after a strong Q2 and continued international expansion.
Want a deeper read on PODD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Aberdeen Group plc Sells 249,355 Shares of Insulet Corporation $PODD
defenseworld.net · Nov 20
Insulet Corporation (PODD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
This Insulet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
benzinga.com · Nov 18
Insulet Corporation $PODD Stock Position Boosted by Fifth Third Bancorp
defenseworld.net · Nov 16
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
zacks.com · Nov 12
Insulet (PODD) Just Overtook the 20-Day Moving Average
zacks.com · Nov 12
Insulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter
seekingalpha.com · Nov 11
Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice